Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ACME LaboratoriesDHA:ACMELAB -0.12%91 PS Ratio is 0.60 as of Jul. 15, 2026, which is 21% below its 10-year median of 0.76. GuruFocus rates DHA:ACMELAB with a GF Score™ of 91/100 and a GF Value™ of BDT125.72 (Possible Value Trap). The stock has 8 warning signs investors should review. Among 955 Drug Manufacturers companies, ACME Laboratories ranks better than 84.5% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, ACME Laboratories's share price is BDT86.80.
ACME Laboratories's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was BDT144.00. Hence, ACME Laboratories's PS Ratio for today is 0.60.
Warning Sign:
ACME Laboratories Ltd stock PS Ratio (=0.59) is close to 2-year high of 0.61.
The historical rank and industry rank for ACME Laboratories's PS Ratio or its related term are showing as below:
DHA:ACMELAB'
s PS Ratio Range Over the Past 10 Years
Min: 0.42 Med: 0.76 Max: 1.87
Current: 0.61
During the past 9 years, ACME Laboratories's highest PS Ratio was 1.87. The lowest was 0.42. And the median was 0.76.
DHA:ACMELAB's PS Ratio is ranked better than 84.5% of 955
companies
in the Drug Manufacturers industry
Industry Median: 2.35
vs DHA:ACMELAB: 0.61
During the past 12 months, the average Revenue per Share Growth Rate of ACME Laboratories was 18.60% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 15.40% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 13.90% per year.
During the past 9 years, ACME Laboratories's highest 3-Year average Revenue per Share Growth Rate was 15.40% per year. The lowest was 11.90% per year. And the median was 12.30% per year.
Back to Basics: PS Ratio
ACME Laboratories (DHA:ACMELAB) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
ACME Laboratories PS Ratio Related Terms
ACME Laboratories PS Ratio Historical Data
* Premium members only.
The historical data trend for ACME Laboratories's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:ACMELAB vs ZTS, UTHR, VTRS: PS Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, ACME Laboratories's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ACME Laboratories PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ACME Laboratories's PS Ratio distribution charts can be found below:
* The bar in red indicates where ACME Laboratories's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
ACME Laboratories's Share Price of today is BDT86.80. ACME Laboratories's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT144.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
ACME Laboratories (DHA:ACMELAB) has a PS Ratio of 0.60 as of Jul. 15, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on ACME Laboratories and its competitors. This is 21% below median its historical median of 0.76. Over the past decade, ACME Laboratories' PS Ratio has ranged from 0.42 to 1.87. According to the industry distribution chart, ACME Laboratories ranks #148 out of 955 companies in the Drug Manufacturers industry, placing it in the top 15.5%.
Is ACME Laboratories' PS Ratio too high?
ACME Laboratories' current PS Ratio of 0.60 is 21% below median its 10-year median of 0.76. Over the past 10 years, this metric has ranged from a low of 0.42 to a high of 1.87. The Drug Manufacturers industry median PS Ratio is 2.35. ACME Laboratories' value of 0.60 is 74.5% below this industry median. Based on the distribution chart, ACME Laboratories ranks #148 out of 955 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, ACME Laboratories has a GF Score™ of 91/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ACME Laboratories' PS Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, ACME Laboratories ranks #148 out of 955 companies for PS Ratio. This places ACME Laboratories in the top 16% of its industry — outperforming the majority of peers. The industry median PS Ratio is 2.35. ACME Laboratories' value of 0.60 is 74.5% below this benchmark. Historically, ACME Laboratories' own PS Ratio has ranged from 0.42 to 1.87 over the past decade. While the company's 10-year median is 0.76 vs. the industry median of 2.35, ACME Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.35, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ACME Laboratories's current PS Ratio of 0.60 is 74.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on ACME Laboratories and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ACME Laboratories's current PS Ratio is 0.60, which is 21% below median its own 10-year median of 0.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACME Laboratories stock overvalued right now?
Based on GuruFocus' analysis, ACME Laboratories (DHA:ACMELAB) is currently considered Possible Value Trap. The stock's GF Value™ is BDT125.72, compared to a current price of BDT86.80 — trading 31% below its estimated fair value. The current PS Ratio is 0.60, which is 21% below median its 10-year median of 0.76 and 74.5% below the Drug Manufacturers industry median of 2.35. ACME Laboratories' overall GF Score™ is 91/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For ACME Laboratories (DHA:ACMELAB), the current PS Ratio is 0.60 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ACME Laboratories (DHA:ACMELAB) Overvalued in 2026?
Based on GuruFocus' analysis, ACME Laboratories stock appears to be undervalued.
The current stock price of BDT86.80 is trading 31% below its estimated GF Value™ of BDT125.72.
GuruFocus considers ACME Laboratories to be Possible Value Trap.
Key valuation signals for DHA:ACMELAB:
PS Ratio: 0.60 (21% below median its 10-year median of 0.76)
GF Value™: BDT125.72 vs. price of BDT86.80 (31% below fair value)
Industry Position: 74.5% below the Drug Manufacturers median (#148 of 955)
No single metric tells the full story. See the DHA:ACMELAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ACME Laboratories Ltd is engaged in the manufacturing, marketing, and distribution of generic pharmaceutical products in Bangladesh. The Company is engaged in manufacturing, marketing, and distribution of generic pharmaceuticals formulation products which includes human drugs comprising dosages form like a tablet, capsule, dry syrup, cream, ointment, powder, injection, dry powder inhaler, metered dosage inhaler, suppository, eye and nasal drop, liquid, liquid in hard gelatine, Blow Fill Seal (BFS) products, sachet products; veterinary drugs comprising dosages form like bolus, liquid,injection, water-soluble powder, premix and herbal drugs comprising dosages form like liquid, capsule, tablet, cream. The products of the company are sold in domestic and international markets.
91GF Score
Get the complete analysis for DHA:ACMELAB
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ACMELAB has been successfully added to your 
